Tag Archives: type 2 diabetes

UCL-led study: Scientists closer to understanding the genetic causes of type 2 diabetes

Scientists are closer to understanding the genetic causes of type 2 diabetes by identifying 111 new chromosome locations (‘loci’) on the human genome that indicate susceptibility to the disease, according to a UCL-led study in collaboration with Imperial College London.  … Read the full press release

Study: BAME patients underrepresented or excluded in clinical trials for diabetes treatments

NOTTINGHAM, 04-Oct-2016 — /EuropaWire/ — Failure to assess people’s language skills when recruiting patients to clinical trials for diabetes treatments may be leading to black, Asian and ethnic minority (BAME) patients being underrepresented or excluded, says a new study. BAME patients … Read the full press release

AstraZeneca/ Karolinska Institutet research points to novel targets for next generation medicines for type 2 diabetes, obesity and other metabolic disorders

STOCKHOLM, 27-Sep-2016 — /EuropaWire/ — New understanding of how hormone-producing cells in the pancreas decode their genetic instructions is pointing to novel targets for next generation medicines for type 2 diabetes, obesity and other metabolic disorders. A large scale analysis of … Read the full press release

New programme launched to raise awareness of Type 2 diabetes in ethnic minority communities in Leicestershire

Leicestershire, UK, 20-Sep-2016 — /EuropaWire/ — A new drive to raise awareness of Type 2 diabetes in ethnic minority communities in Leicestershire has been launched. A six-month programme of activities, including dancing sessions and healthy eating workshops, has started in a … Read the full press release

University of Liverpool: Researchers improved the understanding of the processes that can lead to the development of type 2 diabetes

LIVERPOOL, 12-11-2015 — /EuropaWire/ — Researchers from the University of Liverpool, working with colleagues from Oxford and international partners, have improved the understanding of the processes that can lead to the development of type 2 diabetes. The research, published in Nature Genetics, shows … Read the full press release

Sanofi: LixiLan-L Phase III clinical trial met its primary endpoint in patients with type 2 diabetes treated with insulin glargine with or without metformin

LixiLan met primary endpoint showing superior reduction in HbA1c vs Insulin Glargine alone PARIS, 14-9-2015 — /EuropaWire/ —  Sanofi announced today that the LixiLan-L Phase III clinical trial met its primary endpoint in patients with type 2 diabetes treated with insulin glargine with … Read the full press release

Boehringer Ingelheim, Eli Lilly announce positive top-line results from EMPA-REG OUTCOME

Ingelheim, Germany and Indianapolis, US, 24-8-2015 — /EuropaWire/ — Boehringer Ingelheim and Eli Lilly and Company today announced positive top-line results from EMPA-REG OUTCOME®. This is a long-term clinical trial investigating cardiovascular (CV) outcomes for Jardiance® (empagliflozin) in more than 7,000 … Read the full press release

Boehringer Ingelheim: Phase III clinical trial found that empagliflozin in combination with metformin reduces blood glucose levels in adults with type 2 diabetes

Initial combinations of empagliflozin and metformin in patients with T2D led to significant reductions in blood glucose vs. empagliflozin or metformin alone at 24 weeks Ingelheim, Germany and Indianapolis, US, 8-6-2015 — /EuropaWire/ — A Phase III clinical trial has … Read the full press release

UCL and the University of Zurich study reveals that people with type 2 diabetes are physically less able to recover from stress

People with type 2 diabetes are physically less able to recover from stress, finds a study by scientists at UCL and the University of Zurich, funded by the British Heart Foundation. LONDON, 22-10-2014 — /EuropaWire/ — These findings could lead … Read the full press release

AstraZeneca and Bristol-Myers Squibb Company announce US FDA approved FARXIGA™ (dapagliflozin) for type 2 diabetes adult patients treatment

London, UK, 15-1-2014 — /EuropaWire/ — AstraZeneca and Bristol-Myers Squibb Company announced the US Food and Drug Administration (FDA) approved FARXIGA™ [far-SEE-ga] (dapagliflozin), a once-daily oral treatment indicated as an adjunct to diet and exercise to improve glycaemic control in adults with … Read the full press release

Boehringer Ingelheim and Eli Lilly presented clinical trials results evaluating linagliptin efficacy and safety in Asians with Type 2 Diabetes

2-7-2013 — /europawire.eu/ — New Phase III data presented at the American Diabetes Association 73rd Scientific Sessions® (ADA) showed linagliptin improved blood glucose control as monotherapy and in combination with metformin, in Asian people from China, Malaysia and the Philippines with … Read the full press release

Boehringer Ingelheim, Lilly released results of new meta-analysis regarding CV events in linagliptin Phase 3 trials presented at the American Diabetes Association

Ingelheim, Germany and Indianapolis, US, 1-7-2013 — /europawire.eu/ — Boehringer Ingelheim and Eli Lilly and Company today announced results from a new analysis of Phase III data demonstrating that treatment with the dipeptidyl peptidase-4 (DPP-4) inhibitor linagliptin is not associated with … Read the full press release

SAVOR-TIMI-53 cardiovascular outcomes trial of ONGLYZA® results announced by AstraZeneca and Bristol-Myers Squibb

20-6-2013 — /europawire.eu/ — AstraZeneca and Bristol-Myers Squibb announced today top-line results of the Phase IV SAVOR-TIMI-53 (Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus) clinical trial of Onglyza ® (saxagliptin). In this study of adult patients with … Read the full press release